Summary

Treatment of hemophilia A is benefiting from extended half-life recombinant factor VIII compounds that maintain higher trough levels of drug with less frequent dosing. A variety of pegylated recombinant factor VIII compounds are available. A promising avenue of treatment is the targeted use of liver mesenchymal stem cells that produce factor VIII.